Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis.
Saved in:
| Title: | Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. |
|---|---|
| Authors: | Yang, Ming‐Han1 (AUTHOR), Huang, Chiun‐Sheng2,3 (AUTHOR), Chang, Dwan‐Ying1 (AUTHOR), Hu, Fu‐Chang4,5 (AUTHOR), Huang, Shu‐Min1 (AUTHOR), Huang, Po‐Hsiang1 (AUTHOR), Chen, I‐Chun1,6,7 (AUTHOR), Chen, Tom Wei‐Wu1,7 (AUTHOR), Lin, Ching‐Hung1,3,6 (AUTHOR), Lu, Yen‐Shen1,3 (AUTHOR) yslu@ntu.edu.tw |
| Source: | Cancer Medicine. Jul2024, Vol. 13 Issue 14, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.70005 |
